User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8303

Interactions with Platform & by Email *

INTERACTIONS

1162

Unique # Participated *

PARTICIPANTS

249

Responses Validated *

VALIDATIONS

47

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Cardiovascular Disease – The Undying Challenge.....II-1
World Pharmaceutical Market and Cardiovascular Drugs Dominance.....II-1
1$100
   Table 1: World Pharmaceutical Market - Leading Pharmaceutical Companies Ranked by Global Sales and their Leading Product (in US$ Million): 2008 (includes corresponding Graph/Chart).....II-21$350
   Table 2: World Pharmaceutical Research & Development - Leading Pharmaceutical Companies Ranked in Order of Pharmaceutical R&D Investment (in US$ million): 2008 (includes corresponding Graph/Chart).....II-3
World Cardiovascular Drugs Market.....II-3
2$350
   Table 3: World Cardiovascular Drugs Market - Value Sales of Leading Drugs: 2008 (includes corresponding Graph/Chart).....II-51$350
   Table 4: Select Leading Myocardial Infarction Drugs Worldwide: Value Sales for 2007 and 2008 in US$ Million.....II-6

Table 5: Select Leading Coronary Artery Disease/ Atherosclerosis Drugs Worldwide: Value Sales for 2007 and 2008 in US$ Million.....II-6

Table 6: Select Leading Congestive Heart Failure Drugs Worldwide: Value Sales for 2007 and 2008 in US$ Million.....II-6
1$350
   Table 7: Select Leading Angina Drugs Worldwide: Value Sales for 2007 and 2008 in US$ Million.....II-7

Table 8: Estimated Number of Products Available for Select Cardiovascular Indications (includes corresponding Graph/Chart).....II-7
Cardiovascular Drug Categories At A Glance.....II-7
Antihypertensives.....II-7
Antihyperlipidemics.....II-7
1$350
   Anticoagulants.....II-8
Antiplatelets.....II-8
Growth Drivers / Market Accelerators.....II-8
Combination Products.....II-8
Drug Delivery Technologies.....II-8
1$100
   Growth Inhibitors / Market Challengers.....II-9
Patent Expiry of Best Selling Products.....II-9
List of Leading Cardiovascular Drugs with Upcoming Patent Expiries.....II-9
1$100
   Lack of Product Differentiation.....II-10
Fewer Product Introductions.....II-10
Growing Health Care Expenditure.....II-10
World Cardiovascular Drugs Market Outlook.....II-10
Cardiovascular Drugs Market – Current & Future Analysis.....II-10
By Geographic Region.....II-10
1$100
   By Drug Class.....II-11
Cholesterol Reducing Drugs Lead the Way.....II-11
Angiotensin II Receptor Blockers – The Second Largest Drug Category.....II-11
Antithrombotics – An Active Area of Reasearch and Development.....II-11
1$100
   United States and Europe – Far Ahead and Far More Powerful.....II-12
Anticoagulants – Remarkable Drug Development Potential.....II-12
Anticoagulants to Lose UA/AMI Indications to Antiplatelets.....II-12
1$100
   Novel Anticoagulants to Drive Atrial Fibrillation Drug Market.....II-13
Lack of R&D Innovation, Genericization Characterize the Antihypertensives
  Category.....II-13
Protein Therapy Research Promises Cardiovascular Disease Treatment.....II-13
1$100
   Cardiovascular Disease - Description.....II-14
Atherosclerosis - Leading Cause of Cardiovascular Disease.....II-14
An Insight into the Risk Factors.....II-14
Controllable Risk Factors.....II-14
High Blood Cholesterol.....II-14
1$100
   HDL Cholesterol.....II-15
HDL Cholesterol Levels and Potential Risk of Cardiovascular Disease.....II-15
LDL Cholesterol.....II-15
LDL Cholesterol Levels and Potential Risk of Cardiovascular Disease.....II-15
1$100
   Triglyceride Levels.....II-16
Triglyceride Level and Potential Risk of Cardiovascular Disease.....II-16
High Blood Pressure.....II-16
Obesity.....II-16
1$100
   Smoking.....II-17
Uncontrollable Risk Factors.....II-17
Age.....II-17
Gender.....II-17
Heredity / Ethnicity.....II-17
Diabetes.....II-17
1$100
   Other Risk Factors.....II-18
Stress.....II-18
Alcohol.....II-18
Sedentary Lifestyle/ Physical Inactivity.....II-18
Diseases of the Heart.....II-18
Angina.....II-18
1$100
   Causes and Symptoms.....II-19
Treatment with Drugs.....II-19
Cardiac Arrest.....II-19
Causes and Symptoms.....II-19
Cardiomyopathy.....II-19
1$100
   Ischemic Cardiomyopathy.....II-20
Non-ischemic Cardiomyopathies.....II-20
1$100
   Arrhythmogenic Right Ventricular Dysplasia.....II-21
Causes and Symptoms.....II-21
Treatment with Drugs.....II-21
1$100
   List of Drugs Used for the Treatment of Ischemic Cardiomyopathy, Non-ischemic
  Cardiomyopathies (Hypertrophic, Dilated and Restrictive), and
    Arrhythmogenic Right Ventricular Dysplasia.....II-22
Congestive Heart Failure.....II-22
1$100
   Heart Failure Classification as per the NYHA and ACC/AHA.....II-23
Table 9: Prevalence Rates of Congestive Heart Failure in Select Countries (per 10,000) (includes corresponding Graph/Chart).....II-23
Causes and Symptoms.....II-23
1$350
   List of Causes of Left Side and Right Side Heart Failure.....II-24
Treatment with Drugs.....II-24
1$100
   ACE Inhibitors.....II-25
Aldosterone Blockers.....II-25
Angiotensin II Receptor Blockers.....II-25
Beta-blockers.....II-25
Diuretics.....II-25
Coronary Artery Disease.....II-25
1$100
   Causes and Symptoms.....II-26
Treatment with Drugs.....II-26
1$100
   Myocardial Infarction.....II-27
Causes and Symptoms.....II-27
Treatment with Drugs.....II-27
1$100
   Congenital Heart Disease.....II-28
Cyanotic and Non-cyanotic Congenital Heart Disease.....II-28
Causes and Symptoms.....II-28
Treatment with Drugs.....II-28
1$100
   Beta-blockers.....II-29
Calcium Channel Blockers.....II-29
Angiotensin II Receptor Blockers.....II-29
ACE Inhibitors.....II-29
Diuretics.....II-29
Pericardial Disease.....II-29
1$100
   Causes and Symptoms.....II-30
Valvular Heart Disease.....II-30
Causes and Symptoms.....II-30
1$100
   Diseases of the Blood Vessels.....II-31
Aneurysm.....II-31
Causes and Symptoms.....II-31
1$100
   Different Types of Aneurysm and their Signs and Symptoms.....II-32
Atherosclerosis & Arteriosclerosis.....II-32
1$100
   Causes and Symptoms.....II-33
Treatment with Drugs.....II-33
Statins.....II-33
1$100
   Antiplatelets.....II-34
Anticoagulants.....II-34
Antihypertensives.....II-34
Hypertension.....II-34
Blood Pressure Levels (in adults aged 18 and above) and Risk of Cardiovascular
  Disease.....II-34
1$100
   Primary Hypertension.....II-35
Secondary Hypertension.....II-35
Causes and Symptoms.....II-35
Treatment with Drugs.....II-35
1$100
   Lymphedema.....II-36
Causes and Symptoms.....II-36
Treatment with Drugs.....II-36
Peripheral Arterial Disease.....II-36
1$100
   Causes and Symptoms.....II-37
Treatment with Drugs.....II-37
Stroke.....II-37
1$100
   Types of Ischemic Strokes and Hemorrhagic Strokes and their Description.....II-38
Causes and Symptoms.....II-38
Treatment with Drugs.....II-38
1$100
   Vasculitis.....II-39
Causes and Symptoms.....II-39
Treatment with Drugs.....II-39
1$100
   Adrenergic Blockers.....II-40
Indications for Cardiovascular Diseases:.....II-40
1$100
   List of Indications for Different Types of Alpha-blockers.....II-41
List of Indications for Different Types of Beta-blockers.....II-41
Angiotensin Converting Enzyme Inhibitors.....II-41
1$100
   List of Different Types of ACE Inhibitors and Products.....II-42
Indications for Cardiovascular Diseases:.....II-42
Angiotensin II Receptor Antagonists.....II-42
1$100
   List of Different Types of Angiotensin II Receptor Antagonists and Products.....II-43
Indications for Cardiovascular Diseases:.....II-43
Anticoagulants.....II-43
1$100
   Anticoagulant Drug Classes.....II-44
Oral Anticoagulants.....II-44
Warfarin.....II-44
Coumadin.....II-44
1$100
   Injectable Anticoagulants.....II-45
Heparin.....II-45
1$100
   Unfractionated Heparin.....II-46
Low Molecular Weight Heparin.....II-46
Indications for Cardiovascular Diseases:.....II-46
Antiarrhythmics.....II-46
1$100
   List of Different Types of Antiarrhythmic Drugs and Products.....II-471$100
   Antihyperlipidemics.....II-48
Indications for Cardiovascular Diseases:.....II-48
Antiplatelets.....II-48
1$100
   Indications for Cardiovascular Diseases:.....II-49
List of Indications for Select Antiplatelet Drugs.....II-49
Calcium Channel Blockers.....II-49
1$100
   Indications for Cardiovascular Diseases:.....II-50
List of Indications for Select Calcium Channel Blockers.....II-50
Diuretics.....II-50
1$100
   List of Different Classes and Types of Diuretics.....II-51
Indications for Cardiovascular Diseases:.....II-51
Thrombolytics.....II-51
1$100
   Indications for Cardiovascular Diseases:.....II-52
Vasodilators.....II-52
List of Types of Vasodilators and Brand Names.....II-52
Others.....II-52
1$100
   Table 10: Estimated Number of Candidates in Development Phase by Select Cardiovascular Indication (includes corresponding Graph/Chart).....II-531$350
   Table 11: Estimated Number of Pipeline Products by Select Cardiovascular Indication (includes corresponding Graph/Chart).....II-54
Cardiovascular Pipeline Phase III.....II-54
List of Cardiovascular Pipeline Products in Phase III Development (as of March
  2007).....II-54
2$350
   Cardiovascular Pipeline Phase II.....II-56
List of Cardiovascular Pipeline Products in Phase II Development (as of March
  2007).....II-56
2$125
   Cardiovascular Pipeline Phase I.....II-58
List of Cardiovascular Pipeline Products in Phase I Development (as of March
  2007).....II-58
2$125
   Cardiovascular Pipeline Preclinical Development.....II-60
List of Cardiovascular Pipeline Products in Preclinical Development (as of March
  2007).....II-60
3$175
   Sanofi-aventis and BMS Announce Results of ACTIVE A Phase III Study.....II-63
Takeda’s TAK-536 Reaches Phase III Clinical Trials in Japan.....II-63
China Pharma Commences Clinical Trials for Candesartan Generic.....II-63
Gilead Sciences Announces Phase III Results of Ambrisentan.....II-63
1$100
   Taipei Medical University Reveals Results of New Blood Pressure Study.....II-64
Researchers Identify New Genes Affecting Blood Pressure.....II-64
Italian Study Demonstrates Benefits of Investigational Amlodipine and Telmisartan
  Combination Treatment in Blood Pressure Patients Exposed to Risk of Cardiovascular
    Events.....II-64
1$100
   Gilead Sciences Announces Phase III Darusentan Data.....II-65
Gilead Sciences Commences Phase II Trial of Cicletanine.....II-65
BMS and Pfizer Announce APPRAISE-1 Results for Apixaban.....II-65
Surface Logix Announces Encouraging Phase IIa Results of SLx-2101.....II-65
1$100
   Daiichi Sankyo Commences Phase III Clinical Trial for DU-176b.....II-66
New Clinical Data Demonstrates Effectiveness of Rasilez/Tekturna in Obese Patients with
  Hypertension in Comparison to Monotherapy with Diuretic
    Hydrochlorothiazide.....II-66
New Study Demonstrates Effectiveness of Exforge® in Controlling High Blood Pressure in
  "difficult-to-treat" Patients than Amlodipine Alone.....II-66
1$100
   New Analyses Demonstrates Use of Cleviprex for Controlling Perioperative Hypertension
  to Lower the Risk of Heart Attack and Mortality Following Cardiac Surgery.....II-67
Observational Study Demonstrates Telmisartan to Provide Powerful Blood Pressure Control
  for Complete 24-hours, Including the Risky Hours of Early Morning.....II-67
New Study Demonstrates Tekturna® When Combined with Diovan® to Have Additional Blood
  Pressure Lowering Effect.....II-67
1$100
   Protherics Develops High Blood Pressure Vaccine.....II-681$100
   Sanofi-aventis Mexico Takes Over Laboratorios Kendrick.....II-69
Sanofi-aventis Takes Over Helvepharm.....II-69
Gilead Announces Agreement to Acquire CV Therapeutics.....II-69
Arca biopharma Merges with Nuvelo.....II-69
1$100
   Merck Merges Business with Schering-Plough.....II-70
Zydus Cadila Joins Forces with Eli Lilly for Cardiovascular Drug Research.....II-70
Actelion and GeneraMedix Sign Definitive Agreement.....II-70
AtCor Medical Enters into Contract with Pharmaceutical Company.....II-70
Daiichi Sankyo Sets Up Puerto Rican Subsidiary.....II-70
1$100
   Wuzhou Pharma Secures Patent for Cardiovascular Drug.....II-71
Pfizer Completes Encysive Pharmaceuticals Acquisition.....II-71
Daiichi Sankyo Acquires Majority Interest in Ranbaxy.....II-71
1$100
   GlaxoSmithKline Acquires Bristol Myers Squibb’s Egyptian Business.....II-72
Gilead Sciences Acquires Navitas’ Cicletanine Business Assets.....II-72
Shionogi Acquires Sciele Pharma.....II-72
GlaxoSmithKline Acquires Reliant Pharmaceuticals.....II-72
1$100
   Recordati Acquires Yeni Ilac.....II-73
Sinobiopharma Acquires DongYing Pharmaceutical.....II-73
Advent International Takes Over LaborMed Pharma.....II-73
1$100
   Wyeth Pharmaceuticals Takes Over Thiakis Limited.....II-74
Jenson Services Acquires Majority Stake in LipidViro Tech.....II-74
King Pharmaceuticals to Acquire Alpharma.....II-74
China Sky One to Take Over Heilongjiang Tianlong Pharmaceutical.....II-74
1$100
   GlaxoSmithKline to Acquire Bristol-Myers Squibb Pakistan.....II-75
Meda Signs Deal to Take Over Roche Pharmaceutical Products.....II-75
Kyowa Hakko Merges with Kirin Pharma.....II-75
Belupo and Farmavita Announce Merger.....II-75
Cardiovascular Systems Merges with Replidyne.....II-75
1$100
   Iroko Acquires Aggrastat’s Rights from Merck.....II-76
DAIICHI SANKYO ILAÇ Acquires Antihypertensive Drug, Concor.....II-76
PAION Announces Acquisition of Global Rights to Trigen’s flovagatran.....II-76
Daiichi Sankyo India and GlaxoSmithKline Sign Co-Promotion Deal.....II-76
Exelixis and Bristol-Myers Squibb Announce Collaboration.....II-76
1$100
   Sciele Pharma and Addrenex Pharmaceuticals Sign Exclusive Agreement.....II-77
Biological E Collaborates with Choncept and Heparinex.....II-77
Merck Extends Licensing Agreement with AstraZeneca.....II-77
1$100
   Merck Serono Signs Distribution Agreement with Bristol-Myers Squibb.....II-78
Quantum Genomics and PCAS Pharma Sign Strategic Agreement.....II-78
Forest Laboratories Holdings Amends Agreement with Mylan.....II-78
BMS and KAI Sign Pact to Develop, Commercialize Cardiovascular Drug.....II-78
1$100
   CV Therapeutics and Menarini Group Sign Deal for Ranexa.....II-79
VIA Pharma Signs Deal with Roche for Cardiovascular Drug Candidates.....II-79
Ranbaxy Pharmaceuticals and AstraZeneca Sign Agreements.....II-79
1$100
   pSivida Signs Technology Evaluation Agreement for Cardiovascular Drug Delivery.....II-80
Recordati Completes Mutual Recognition with 28 European Nations.....II-80
Forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion Agreement.....II-80
1$100
   Daiichi Sankyo Establishes Subsidiary in Ireland.....II-81
Kampala Pharma to Commence Production of High Blood Pressure Drugs.....II-81
Daiichi Sankyo Submits Application for Antihypertensive Drug Approval.....II-81
Zydus Cadila Submits IND Application for Cardiovascular Medicine.....II-81
Actelion and Merck Initiate Phase II Program Dosing, Reach Fourth Milestone.....II-81
1$100
   Pfizer Wins Patent Protection Lawsuit for Norvasc in Canada.....II-82
Pharmaceutical Holdings Changes Name to URL Pharma.....II-82
Lupin Acquires Majority Interest in Kyowa Pharmaceutical.....II-82
Merck Acquires NovaCardia.....II-82
1$100
   QuantRX Acquires Additional Stake in FluoroPharma.....II-83
SMI Products Acquires Nile Therapeutics.....II-83
Krka to Acquire German Company, TAD Pharma.....II-83
Private Group to Acquire Majority Stake in Inyx.....II-83
Jupiter Bioscience Acquires Drug Technology.....II-83
The Medicines Company Re-acquires European Rights for Angiox.....II-83
1$100
   Sanofi-aventis Acquires Rights for Panaldine from Daiichi Sankyo.....II-84
Corautus Genetics and VIA Pharmaceuticals Sign Merger Agreement.....II-84
Cardiome and Eli-Lilly Ink Exclusive In-Licensing Deal.....II-84
1$100
   Alchemia Inks Marketing Alliance with Dr. Reddy’s for Heparin.....II-85
Meda and Recordati Enter into Agreement for Zaneril®.....II-85
Meda and Recordati Sign Long-Term Agreement.....II-85
BMS and Pfizer Announce Collaboration for Apixaban.....II-85
1$100
   BMS and Isis Announce Cardiovascular Disease Collaboration.....II-86
Vasogen Announces Collaboration with Grupo Ferrer Internacional.....II-86
Recordati- Berlin Chemie Expand Licensing Agreement.....II-86
1$100
   Guangdong Luote Signs Agreement with Nippon Chemiphar.....II-87
Suven to Sign Cardiovascular Drugs Development Agreement with US Firm.....II-87
Kaken to Commence Marketing Procylin for Pulmonary Hypertension Treatment.....II-87
Par Pharmaceuticals Ships ER Metoprolol Succinate Tablets.....II-87
1$100
   Biovail Reaches Settlement Agreement with Watson Pharmaceuticals.....II-88
Lexicon Genetics Announces Name Change.....II-88
1$100
   Sanofi-aventis Wins FDA Approval for Multaq.....II-89
CV Therapeutics Introduces Ranexa® in Germany and the UK.....II-89
Takeda Introduces ECARD for Hypertension Treatment.....II-89
Amneal Pharmaceuticals Introduces Benazepril HCI.....II-89
1$100
   Ranbaxy Laboratories to Introduce Daiichi Sankyo's Olvance in India.....II-90
Gemini Pharmaceuticals Launches Antihypertensive Medicine, Micardis.....II-90
Shionogi Introduces Fluitran® 1mg.....II-90
Helvepharm Launches New Antihypertensive Drug.....II-90
Ranbaxy Laboratories Introduces Amlodipine.....II-90
Nicholas Piramal Launches Hypertension Management Device.....II-90
1$100
   GlaxoSmithKline Introduces Ambrisentan.....II-91
Novartis Introduces Aliskiren.....II-91
Dainippon Introduces Avapro for Hypertension Treatment.....II-91
Shionogi Introduces Irbetan for Hypertension Treatment.....II-91
Pfizer Japan Introduces Sildenafil.....II-91
Surgipharm Launches Diovan and Co-diovan.....II-91
1$100
   King Pharmaceuticals Introduces Altace Tablets.....II-92
Encysive Pharmaceuticals Introduces Thelin Tablets.....II-92
Dr Reddy's Laboratories Introduces Atocor-R.....II-92
CV Therapeutics Rolls Out Ranexa® 1000 mg Tablet.....II-92
Wockhardt to Introduce Amlodipine Tablets.....II-92
1$100
   GlaxoSmithKline Launches Coreg CR Extended- Release Capsules.....II-93
Toray and Astellas Introduce Careload LA Tablets.....II-93
AstraZeneca Introduces Crestor.....II-93
Torrent Pharma Introduces CVpill.....II-93
Ranbaxy Laboratories Introduces Generic Drug Verapamil.....II-93
1$100
   Actavis Group Introduces NIFEdipine (XR) Tablets.....II-94
Apotex Introduces Norvasc Generic.....II-94
Novartis Introduces Aliskiren.....II-94
Encysive Introduces Sitaxentan in Ireland.....II-94
Pfizer to Release Generic Version of Norvasc.....II-94
Mylan Introduces Generic Blood Pressure Medicines.....II-94
Encysive Introduces Sitaxentan Encysive in Italy.....II-94
1$100
   GlaxoSmithKline Introduces Carzec.....II-95
Encysive Pharmaceuticals Introduces Thelin in France.....II-95
1$100
   Sanofi-aventis Wins FDA Approval for Multaq.....II-96
Astellas and Nippon Receive Approval for Micombi® Antihypertensive Drug.....II-96
Daiichi Sankyo and Eli Lilly Win EC Approval for Efient®.....II-96
Novartis Wins FDA Approval for Tekturna HCT as Initial Therapy.....II-96
1$100
   The Medicines Co Announces EU Acceptance of MAA for Cleviprex.....II-97
Ranbaxy Secures FDA Clearance for Ramipril Capsules.....II-97
Ranbaxy Receives FDA Approval for Antihypertensive Drug.....II-97
Sun Pharmaceuticals Receives Approval for Generic Version of Accupril.....II-97
United Therapeutics Receives FDA Approval for PH Drug.....II-97
1$100
   Novartis Obtains Approval from Japanese Health Ministry.....II-98
Novartis Obtains FDA Approval for Exforge HCT.....II-98
Novartis Obtains Approval for Four New Medicines.....II-98
Aveva Drug Delivery Obtains Approval for Clonidine TDS.....II-98
Actelion Wins FDA Approval for Tracleer®.....II-98
1$100
   Ranbaxy Receives Canadian Approval to Market Anti- Hypertension Drug.....II-99
Actelion Receives FDA Approval for New Ventavis Formulation.....II-99
Sinobiopharma Receives Chinese Approval for Perindopril.....II-99
Novartis Obtains FDA Approval for Tekturna HCT.....II-99
1$100
   Lupin Receives FDA Approval for Generic Ramipril Capsules.....II-100
Abbott Secures FDA Approval for TriLipix.....II-100
Mylan Receives FDA Approval for Nisoldipine Extended-Release.....II-100
Glenmark Wins FDA Approval for Trandolapril.....II-100
CV Therapeutics Obtains FDA Approval for New Indication for Ranexa.....II-100
1$100
   Mylan Receives Tentative Approval for Generic Version of Benicar HCT.....II-101
Novartis Secures Swissmedic Approval for Rasilez HCT.....II-101
Kyowa Secures Japanese Approval for Amlodipine Generic.....II-101
Novartis Obtains FDA Approval for Exforge and Diovan HCT.....II-101
1$100
   CV Therapeutics Wins EMEA Approval for Brand Name, Ranexa.....II-102
Aurobindo Pharma Obtains FDA Approval.....II-102
Actelion Receives EU Approval for Tracleer.....II-102
The Medicines Company Wins FDA Approval for Cleviprex.....II-102
Indian Pharma Wins Approval for Propranolol Hydrochloride Tablets.....II-102
1$100
   Aurobindo Pharma Secures FDA Approval for Lotensin Generic.....II-103
Zydus Cadila Obtains FDA Approval for Marketing of Benazepril.....II-103
Mylan Wins FDA Approval for Mavik’s Generic.....II-103
Helpson Receives China FDA Approval to Market Bumetanide Generic.....II-103
Sciele Pharma Obtains FDA Approval.....II-103
Novartis’ Rasilez HCT Receives European Committee Recommendation.....II-103
1$100
   Novartis Wins Canadian Approval for Rasilez.....II-104
Dr. Reddy's Receives FDA Approval for Trandolapril.....II-104
GeneraMedix Wins Approval from FDA for Epoprostenol.....II-104
Zydus Cadila Obtains FDA Approval for Ramipril Capsules.....II-104
KV Pharmaceutical Obtains FDA Approval for Toprol-XL Generic.....II-104
1$100
   Recordati Obtains Australian Approval for Zan-Extra®.....II-105
Zydus Cadila Obtains Approval from U.S. FDA for Four Drugs.....II-105
Boehringer Ingelheim Wins EU Commission Approval for MicardisPlus® 80/25.....II-105
Daiichi Sankyo Europe Obtains Marketing Approval of SEVIKAR®.....II-105
GlaxoSmithKline Wins EC Marketing Approval for Volibris.....II-105
1$100
   BioInvent, ThromboGenics Receive Approval for Anticoagulant Clinical Trials.....II-106
Novartis Secures FDA Approval for Exforge.....II-106
Bristol-Myers and Sanofi-aventis Obtain FDA Approval for Avalide.....II-106
Glenmark Wins FDA Approval for Coreg.....II-106
Sanofi-aventis Wins FDA Approval to Use Lovenox in STEMI Patients.....II-106
1$100
   Daiichi Sankyo Wins FDA Approval for Azor.....II-107
Sanofi-aventis, BMS Win FDA Approval for Plavix 300mg.....II-107
Caraco Receives ANDA Approval for Norvasc Generic.....II-107
Mylan and Forest Labs Win FDA Approval to Market Bystolic.....II-107
Teva Bags Approval to Market Accupril Generic.....II-107
1$100
   Ranbaxy Bags Approval to Produce and Market Amlodipine Besylate.....II-108
Caraco Receives FDA Approval for Atenolol Tablets.....II-108
Novartis Wins Swissmedic Approval for Tekturna.....II-108
Lupin Bags Approval to Market Prinivil’s Generic Version.....II-108
Aurobindo Pharma Receives FDA Approval for Accuretic’s Generic Version.....II-108
1$100
   Gilead Sciences Wins FDA Approval for Letairis.....II-109
Wockhardt Wins FDA Approval to Market Lisinopril.....II-109
Pliva Wins FDA Approval for New Products.....II-109
Ranbaxy Wins Approval to Market Atenolol.....II-109
Ranbaxy Receives Health Canada Approval for Lisinopril Tablets.....II-109
1$100
   Ranbaxy Receives Tentative Approval for Valsartan Tablets.....II-110
Par Pharmaceutical Receives FDA Approval for Propranolol HCl ER.....II-110
Ranbaxy Receives Approval from FDA for Coreg Generic.....II-110
KV Pharmaceuticals Obtains FDA Approval for Toprol-XL Generic.....II-110
1$100
   Encysive Pharma Wins Australian Approval for Thelin®.....II-111
Mylan Wins Approval for Propranolol Hydrochloride ER Capsules.....II-111
Novartis Wins EU Approval for Rasilez.....II-111
GlaxoSmithKline Receives FDA Approval for Arixtra Injection.....II-111
GlaxoSmithKline Wins EMEA Approval for Arixtra.....II-111
GlaxoSmithKline Wins MHLW Approval for Arixtra.....II-111
1$100
   Actavis Group Secures FDA Approval for Carvedilol Tablets.....II-1121$100
   Abbott Laboratories Inc. (USA).....II-113
AstraZeneca PLC (UK).....II-113
1$100
   Bayer AG (Germany).....II-114
Biovail Corp. (Canada).....II-114
Boehringer Ingelheim GmbH (Germany).....II-114
1$100
   Bristol-Myers Squibb Company (USA).....II-115
Daiichi Sankyo Company, Ltd. (Japan).....II-115
Forest Laboratories, Inc. (USA).....II-115
1$100
   GlaxoSmithKline PLC (UK).....II-116
Merck & Co., Inc. (USA).....II-116
1$100
   Novartis AG (Switzerland).....II-117
Pfizer, Inc. (USA).....II-117
1$100
   Sanofi-aventis (France).....II-118
Solvay Pharmaceuticals SA (Belgium).....II-118
Takeda Pharmaceutical Company Limited (Japan).....II-118
1$100
   The Medicines Company (USA).....II-1191$100
   Table 12: World Recent Past, Current & Future Analysis for Cardiovascular Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1201$350
   Table 13: World Historic Review for Cardiovascular Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-1211$350
   Table 14: World 13-Year Perspective for Cardiovascular Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for the US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Latin America, and Rest of World Markets for 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-1221$350
   Table 15: World Recent Past, Current & Future Analysis for Cardiovascular Drugs by Drug Class - Cholesterol Reducing Drugs, Angiotensin II Receptor Blockers, Anti-Thrombotics, ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Anti-Arrhythmics, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1231$350
   Table 16: World 9-Year Perspective for Cardiovascular Drugs by Drug Class - Percentage Breakdown of Dollar Sales for Cholesterol Reducing Drugs, Angiotensin II Receptor Blockers, Anti-Thrombotics, ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Anti-Arrhythmics, and Others Markets for 2007, 2009 & 2015 (includes corresponding Graph/Chart).....II-1241$350
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Cardiovascular Disease – Prevalence.....III-1
AHA Statistics for Cardiovascular Disease.....III-1
1$75
   AHA Statistics for Coronary Heart Disease.....III-2
NCHS and NHLBI "Death Due to Cardiovascular Diseases" Data.....III-2
Market Overview.....III-2
1$75
   Table 17: US Cardiovascular Drugs Market - Total Prescriptions by Drug Class (in thousands): 2008 and 2009 (includes corresponding Graph/Chart).....III-31$200
   Table 18: Select Leading Myocardial Infarction Drugs in the US: Value Sales for 2007 and 2008 in US$ Million (includes corresponding Graph/Chart).....III-4

Table 19: Select Leading Coronary Artery Disease/ kAtherosclerosis Drugs in the US: Value Sales for 2007 and 2008 in US$ Million (includes corresponding Graph/Chart).....III-4
1$200
   Table 20: Select Leading Congestive Heart Failure Drugs in the US: Value Sales for 2007 and 2008 in US$ Million (includes corresponding Graph/Chart).....III-5

Table 21: Select Leading Angina Drugs in the US: Value Sales for 2007 and 2008 in US$ Million (includes corresponding Graph/Chart).....III-5
1$200
   Antihypertensives.....III-6
Table 22: US Antihypertensive Drugs Market - Sales and Percentage Share Breakdown by Leading Product in US$ Million Between October 2007 and October 2008 (includes corresponding Graph/Chart).....III-6
1$200
   Prescription Trends.....III-7
Table 23: US Antihypertensive Drugs Market - Percentage Share Breakdown of Total Prescriptions By Leading Product: 2007 (includes corresponding Graph/Chart).....III-7
1$200
   Table 24: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of Total Prescriptions by Leading Class of Drug: 2007, 2008 and 2009 (includes corresponding Graph/Chart).....III-8

Table 25: US Antihypertensive Drugs Market - Percentage Share Breakdown of ACE Inhibitors Based on Total Prescriptions: 2007 (includes corresponding Graph/Chart).....III-8
1$200
   Table 26: US Antihypertensive Drugs Market - Percentage Share Breakdown of Angiotension Receptor Antagonists (ARAs) Based on Total Prescriptions: 2007 (includes corresponding Graph/Chart).....III-9
New Patient Therapy Starts to Witness Slowdown.....III-9
Table 27: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of Angiotensin II Receptor Antagonists in terms of New Prescriptions for 2007, 2008 and 2009 (includes corresponding Graph/Chart).....III-9
1$200
   Table 28: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of ACE Inhibitors in terms of New Prescriptions for 2007, 2008 and 2009 (includes corresponding Graph/Chart).....III-101$200
   Table 29: US Anti-hypertensive Drugs market - Percentage Share Breakdown of Calcium Channel Blockers in terms of New Prescriptions for 2007, 2008 and 2009 (includes corresponding Graph/Chart).....III-11
African Americans At Major Health Risk Due to Hypertension.....III-11
1$200
   Antihyperlipidemics.....III-12
Table 30: US Cardiovascular Drugs Market for Statins (HMG CoA-Reductase Inhibitors) - Type of Statin Ranked by Value Sales (in US$ Million): 2007 (includes corresponding Graph/Chart).....III-12

Table 31: US Cardiovascular Drugs Market for Fibrates (Sales in US$ Million): 2007 (includes corresponding Graph/Chart).....III-12
1$200
   Table 32: US Antihyperlipidemic Drugs Market - Percentage Share Breakdown of Total Prescriptions by Leading Product: 2007 (includes corresponding Graph/Chart).....III-13
Anticoagulants and Antiplatelets.....III-13
Table 33: US Anticoagulant Drugs Market - Percentage Share Breakdown of Total Prescriptions by Leading Product: 2007 (includes corresponding Graph/Chart).....III-13
1$200
   Drug Development Pipeline.....III-14
Competitive Landscape.....III-14
Pharmaceutical.....III-14
Table 34: US Pharmaceutical Market - Leading Pharmaceutical Companies Ranked by Value Sales (in US$ Million): 2008 (includes corresponding Graph/Chart).....III-14
1$200
   Table 35: US Pharmaceutical Market - Leading Pharmaceutical Products Ranked by Value Sales (in US$ Million): 2007 (includes corresponding Graph/Chart).....III-15

Table 36: US Pharmaceuticals Market - Leading Therapeutic Class Ranked by Value Sales (in US$ Million): 2008 (includes corresponding Graph/Chart).....III-15
1$200
   Cardiovascular Drugs.....III-16
Table 37: US Cardiovascular Drugs Market - Leading Companies Ranked by Cardiovascular Drug Sales (in US$ Million): 2008 (includes corresponding Graph/Chart).....III-16
1$200
   Research and Development.....III-172$125
   Strategic Corporate Developments.....III-199$375
   Product Launches.....III-281$75
   Product Approvals.....III-2911$425
   Select Players.....III-403$175
   B. Market Analytics.....III-43
Table 38: US Recent Past, Current & Future Analysis for Cardiovascular Drugs by Drug Class - Cholesterol Reducing Drugs, Angiotensin II Receptor Blockers, Anti-Thrombotics, ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Anti-Arrhythmics, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-43
1$200
   Table 39: US 9-Year Perspective for Cardiovascular Drugs by Drug Class - Percentage Breakdown of Dollar Sales for Cholesterol Reducing Drugs, Angiotensin II Receptor Blockers, Anti-Thrombotics, ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Anti-Arrhythmics, and Other Markets for 2007, 2009 & 2015 (includes corresponding Graph/Chart).....III-441$200
   Table 40: US Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-451$200
   A. Market Analysis.....III-46
Current and Future Analysis.....III-46
Strategic Corporate Development.....III-46
Product Approvals.....III-46
1$75
   B. Market Analytics.....III-47
Table 41: Canadian Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 2006 (includes corresponding Graph/Chart).....III-47
1$200
   Table 42: Canadian Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-481$200
   A. Market Analysis.....III-49
Current and Future Analysis.....III-49
Market Overview.....III-49
Research & Development.....III-49
Strategic Corporate Developments.....III-49
2$125
   Product Launches.....III-511$75
   Product Approvals.....III-521$75
   Select Players.....III-532$125
   B. Market Analytics.....III-55
Table 43: Japanese Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-55
1$200
   Table 44: Japanese Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-561$200
   A. Market Analysis.....III-57
Current and Future Analysis.....III-57
Cardiovascular Disease – Mortality Profile.....III-57
1$75
   Cardiovascular Disease – Risk Factor Profile.....III-58
The Cardiovascular Disease Cost Burden.....III-58
EU to Face Health Care Expenditure Challenge Head-on.....III-58
Research & Development.....III-58
2$125
   Strategic Corporate Developments.....III-604$175
   Product Launches.....III-642$125
   Product Approvals.....III-663$175
   Select Players.....III-694$175
   B. Market Analytics.....III-73
Table 45: European Recent Past, Current & Future Analysis for Cardiovascular Drugs by Region - France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-73
1$200
   Table 46: European Historic Review for Cardiovascular Drugs by Region - France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-741$200
   Table 47: European 13-Year Perspective for Cardiovascular Drugs by Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets for 2003, 2009 & 2015 (includes corresponding Graph/Chart).....III-751$200
   Table 48: European Recent Past, Current & Future Analysis for Cardiovascular Drugs by Drug Class - Cholesterol Reducing Drugs, Angiotensin II Receptor Blockers, Anti-Thrombotics, ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Anti-Arrhythmics, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-761$200
   Table 49: European 9-Year Perspective for Cardiovascular Drugs by Drug Class- Percentage Breakdown of Dollar Sales for Cholesterol educing Drugs, Angiotensin II Receptor Blockers, Anti-Thrombotics, ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Anti- Arrhythmics, and Other Markets for 2007, 2009 & 2015 (includes corresponding Graph/Chart).....III-771$200
   A. Market Analysis.....III-78
Current and Future Analysis.....III-78
B. Market Analytics.....III-78
Table 50: French Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-78
1$200
   Table 51: French Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-791$200
   A. Market Analysis.....III-80
Current and Future Analysis.....III-80
B. Market Analytics.....III-80
Table 52: German Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-80
1$200
   Table 53: German Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-811$200
   A. Market Analysis.....III-82
Current and Future Analysis.....III-82
B. Market Analytics.....III-82
Table 54: Italian Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-82
1$200
   Table 55: Italian Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-831$200
   A. Market Analysis.....III-84
Current and Future Analysis.....III-84
B. Market Analytics.....III-84
Table 56: UK Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-84
1$200
   Table 57: UK Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-851$200
   A. Market Analysis.....III-86
Current and Future Analysis.....III-86
B. Market Analytics.....III-86
Table 58: Spanish Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-86
1$200
   Table 59: Spanish Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-871$200
   A. Market Analysis.....III-88
Current and Future Analysis.....III-88
B. Market Analytics.....III-88
Table 60: Rest of Europe Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-88
1$200
   Table 61: Rest of Europe Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-891$200
   A. Market Analysis.....III-90
Current and Future Analysis.....III-90
Research & Development.....III-90
Strategic Corporate Developments.....III-90
3$175
   Product Launches.....III-931$75
   Product Approvals.....III-942$125
   B. Market Analytics.....III-96
Table 62: Asia Pacific Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-96
1$200
   Table 63: Asia Pacific Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-971$200
   A. Market Analysis.....III-98
Current and Future Analysis.....III-98
Strategic Corporate Developments.....III-98
1$75
   B. Market Analytics.....III-99
Table 64: Latin America Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-99
1$200
   Table 65: Latin America Historic Review for CardiovascularDrugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-1001$200
   A. Market Analysis.....III-101
Current and Future Analysis.....III-101
Strategic Corporate Developments.....III-101
2$125
   Product Launches.....III-103
Product Approval.....III-103
1$75
   B. Market Analytics.....III-104
Table 66: Rest of World Recent Past, Current & Future Analysis for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-104
1$200
   Table 67: Rest of World Historic Review for Cardiovascular Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-1051$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com